40372-00-7

40372-00-7 structure

Name: Taribavirin hydrochloride
Chemical Name: 1-[(2R,3S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide,hydrochloride
CAS Number: 40372-00-7
Molecular Formula: C₈H₁₄ClN₅O₄
Molecular Weight: 279.68100
Catalog: Signaling Pathways Anti-infection HBV
Create Date: 2017-10-14 21:41:00
Modify Date: 2024-01-07 10:37:08
Taribavirin hydrochloride is an inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus[1]. Taribavirin hydrochloride is a Ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia[2].

Name	1-[(2R,3S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboximidamide,hydrochloride
Synonyms	Ribamidine hydrochloride Viramidine hydrochloride 1-\|A-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboximidamide Monohydrochloride AVS 206

Description	Taribavirin hydrochloride is an inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus[1]. Taribavirin hydrochloride is a Ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia[2].
Related Catalog	Signaling Pathways >> Anti-infection >> HCV Research Areas >> Infection Signaling Pathways >> Anti-infection >> HBV
Target	Inosine monophosphate dehydrogenase[1]
In Vitro	Taribavirin hydrochloride (0-2 μM; 24 hours) significantly induces MCF-7 cell death, recording half inhibitory effect (IC50) of 0.756 μM in MCF-7 cells[1]. Cell Viability Assay[1] Cell Line: MCF-7 cells Concentration: 0 μM, 0.1 μM, 1 μM, 2 μM Incubation Time: 24 hours Result: Decreased MCF-7 cell growth.
References	[1]. Abd-Rabou AA, et al. Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer. Pharm Res. 2018 Feb 27;35(4):76. [2]. Deming P, et al. Taribavirin in the treatment of hepatitis C. Expert Opin Investig Drugs. 2011 Oct;20(10):1435-43.

Precursor 0
DownStream 1
36791-04-5